Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd. announced its audited consolidated results for the year ending December 31, 2024, showing a revenue of RMB158.8 million primarily from licensing-out deals and CDMO services. Despite a decrease in research and development expenses and a reduction in loss for the year by 33% compared to 2023, the company still reported a significant loss. The announcement also included proposed amendments to the company’s Articles of Association and changes in the Strategy and Development Committee, indicating strategic shifts that may impact future operations and stakeholder interests.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on research and development services, licensing-out deals, and CDMO (Contract Development and Manufacturing Organization) services, with products such as QX008N and QX004N.
YTD Price Performance: 21.68%
Average Trading Volume: 82,866
Technical Sentiment Signal: Strong Buy
Learn more about 2509 stock on TipRanks’ Stock Analysis page.